Atlas Trials

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

Clinical trial NCT06841705 · RECRUITING

Trial details

NCT number
NCT06841705
Sponsor
Shilpa Grover, MD, MPH
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Immune Checkpoint Inhibitor-Related Colitis
Start date
2025-07-15
Primary completion
2026-07-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.